Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

Merck fell 7% despite an earnings beat as investors focused on a pipeline setback and weakness in Gardasil. Keytruda and newer launches provided offsetting growth support, but the mix of positive earnings and negative product-specific issues leaves the readthrough mildly negative overall.

Analysis

Merck fell 7% despite an earnings beat as investors focused on a pipeline setback and weakness in Gardasil. Keytruda and newer launches provided offsetting growth support, but the mix of positive earnings and negative product-specific issues leaves the readthrough mildly negative overall.